FDA rejects Summit's ivonescimab, finding no significant survival benefit
Summit Therapeutics said Sunday it received a complete response letter on the lung cancer drug it is developing with Akeso. Its Nasdaq shares fell around 13 percent Monday morning.
The US Food and Drug Administration has turned down Summit Therapeutics’ request to market ivonescimab for a type of lung cancer. Summit said Sunday that regulators sent a complete response letter on the company’s lead use of the PD-1 and VEGF medicine.
In that letter, the agency said it did not see substantial evidence the drug works unless patients live longer by a statistically significant margin. Reviewers concluded that holding the cancer back, without a survival gain, did not support approval on benefit and risk. The FDA also declined to look past the drug’s failure, on the first analysis, to extend survival. A ruling had been due by Saturday, Nov. 14, and the agency had made no public statement before the weekend.
The filing sought ivonescimab together with chemotherapy for advanced or metastatic non-squamous non-small cell lung cancer with an EGFR mutation, in patients already treated with tyrosine kinase inhibitors. The evidence was HARMONi, a Phase III trial. Summit has said the FDA told it an overall survival benefit in that study would be required. Patients on ivonescimab plus chemotherapy appeared to survive longer than those on placebo plus chemotherapy, yet the gap was not statistically significant. The delay before worsening was significant: a median of 6.8 months with ivonescimab and 4.4 months with placebo.
The decision delays Summit’s first try at a US approval. The Miami firm directs the program outside China with Akeso, the Chinese originator. In 2022 Summit paid $5 billion for rights in the United States, Canada, Europe, Japan, Latin America, the Middle East and Africa, acquired from Akeso in Zhongshan. The antibody is Summit’s main drug in testing, and it is already approved in China. Earlier, the company had no cancer programs and pursued antibiotic work against infections, none of which succeeded.